Tier 3 — preclinical

Specific Bioactive Collagen Peptides in Osteopenia and Osteoporosis: Long-Term Observation in Postmenopausal Women

Denise Zdzieblik, Steffen Oesser, Daniel König
Journal of Bone Metabolism 2021 28(3):207–213

Bibliography

PubMed
PMID 34520654
PubMed Central
PMC8441537
DOI
10.11005/jbm.2021.28.3.207
Funding
The specific collagen peptides (product name FORTIBONE®) were provided by the GELITA GmbH, Eberbach Germany.
Competing interests
No potential conflict of interest relevant to this article was reported. SO has given scientific lectures that were in parts supported by the GELITA AG. He is also co-inventor of patents concerning the use of collagen peptides. Biohack Blueprint assessment: The declaration of "no potential conflict" is inconsistent with the disclosures in the same paragraph — Oesser is a co-inventor of patents on the mechanism being studied and has received lecture support from the manufacturer. Zdzieblik is affiliated with the CRI, Collagen Research Institute (Kiel, Germany), a research entity closely tied to GELITA. The commercial interest is substantial and directly relevant.

Study snapshot

DesignNon-controlled, open-label, single-arm follow-up observation extending the prior 12-month RCT (König 2018)
ModelPostmenopausal women (amenorrhoea ≥1 year) with reduced bone mineral density (initial DXA T-score ≤ -1 at either lumbar spine or femoral neck)
Samplen=31 entered follow-up (13 from prior treatment group, 18 from prior placebo group); n=23 completed the 4-year total intervention
Intervention5 g/day Fortibone specific bioactive collagen peptides (mean molecular weight ~5 kDa; GELITA AG, Eberbach, Germany) dissolved in 250 mL water, once daily. All follow-up participants received collagen — no placebo arm in the observation phase.
Duration3-year follow-up observation, extending prior 12-month RCT to 4 years total intervention time
EndpointsChange in bone mineral density (BMD, g/cm²) at lumbar spine and femoral neck by DXA; T-scores at both sites; Incidence of osteoporotic fractures during observation; Adverse events

What the study showed, in plain terms

This is the four-year follow-up to an earlier one-year randomised trial (König 2018) that tested whether a daily 5 g dose of a specific bioactive collagen peptide (Fortibone) could improve bone mineral density in postmenopausal women with osteopenia or osteoporosis. In this observational phase, all 31 women who continued received the collagen — including 18 who had originally been in the placebo group of the first trial. There was no placebo comparison in the follow-up itself.

Over four years of total supplementation, bone mineral density in the lumbar spine improved by roughly 6% to 8%, and by roughly 1% to 4% in the femoral neck. For context, postmenopausal women without treatment typically lose bone density year on year, so the direction of change is the opposite of what would be expected. None of the participants suffered an osteoporotic fracture during the observation period. No side effects were reported.

This is a promising signal, but the design has real weaknesses — small sample, no placebo arm during follow-up, and the whole trial was conducted and sponsored by a company that manufactures the tested product. It is best read as supporting the earlier randomised trial's finding rather than as standalone evidence.

Key findings

  • Spine BMD in Group 1 (former treatment group, continuing collagen) increased significantly from follow-up start to 2 years (p=0.006) and to 4 years (p=0.049). Relative gain over the full 4-year period: 5.79%.
  • Spine BMD in Group 2 (former placebo group, now on collagen) increased by 8.16% over the follow-up period, with a trend toward significance for relative change (p=0.059).
  • Femoral neck BMD in Group 1 increased significantly from year 2 to year 4 (p=0.040) and from year 3 to year 4 (p=0.018). Relative change 4.21%.
  • Femoral neck BMD in Group 2 showed a trend toward significance from year 2 to year 4 (p=0.052). Relative change 1.23%.
  • Zero osteoporotic fractures reported in either group over the follow-up period.
  • No adverse events or drop-outs related to the study product.
  • Contextualisation by the authors: annual BMD loss in untreated postmenopausal women is approximately 0.022 g/cm² at spine and 0.013 g/cm² at hip (Finkelstein 2008); the observed 3–8% improvement represents ~7% relative gain versus expected natural loss.

What this study can and cannot tell us

  • No control group during the follow-up — every participant received collagen. Without a concurrent placebo arm, the observed BMD changes cannot be cleanly separated from measurement drift, cohort selection effects (only motivated participants continued), or secular trends.
  • Very small sample size (n=31 entering follow-up, n=23 completing). Statistical power is low; confidence intervals around the effect sizes would be wide.
  • Selection bias in follow-up entry — only 31 of 131 original trial participants continued, and self-selection into continued participation may correlate with adherence and other health behaviours.
  • The DXA precision quoted (~1.1%) implies a clinically relevant change requires ~3% BMD movement. Some of the reported changes, particularly at femoral neck for Group 2 (1.23%), fall below this threshold.
  • Substantial industry involvement: GELITA supplied the product and the two lead authors have direct commercial or IP ties. The formal COI declaration is inconsistent with the disclosures made in the same section.
  • Findings apply only to the specific Fortibone hydrolysate tested (~5 kDa mean MW). Different collagen peptides differ in composition and bioavailability, so results cannot be extrapolated to other collagen products.
  • No mechanistic biomarker data collected in the follow-up (unlike the original RCT which measured P1NP and CTX-1). The pathway from ingestion to BMD change is inferred, not directly demonstrated in this study.

Related papers in the corpus

Tier 2
Specific Collagen Peptides Improve Bone Mineral Density and Bone Markers in Postmenopausal Women — A Randomized Controlled Study
Daniel König et al. · Nutrients · 2018

Citation network

Articles citing this research paper

2 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology